A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects With Renal and/or Hepatic Impairment

Trial Profile

A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects With Renal and/or Hepatic Impairment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Tenofovir alafenamide (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 10 Jul 2017 Planned End Date changed from 1 Dec 2020 to 1 Feb 2021.
    • 10 Jul 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Apr 2019.
    • 10 Jul 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top